Abstract
This Viewpoint discusses the regulatory and financial barriers to cannabis research, and the potential changes to these barriers if cannabis is reclassified as a Schedule III drug.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have